Sanofi acquires Blueprint Medicines Corporation for $9.1bn, gaining revenue-driving Aykavit and pipeline drug BLU-808 ...

The Food and Drug Administration approved the drug for adult patients with bullous pemphigoid, which mainly affects the ...

Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the US Food and Drug Administration (FDA) to treat bullous ...

SNY and REGN's Dupixent gets FDA approval for a rare and chronic skin disease, marking its eighth approved indication for the ...

Paris: Sanofi has announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has ...

Sanofi (ENXTPA:SAN) experienced a 4% decline over the past week despite a largely unchanged market. The recent events, including the FDA approval of Dupixent for a rare skin condition and the signing ...

Dupixent approved by FDA for bullous pemphigoid, offering a new option for adults with the rare autoimmune skin disease ...

BIO was as busy as ever in Boston this year. With more to come soon, here are a few initial thoughts on three events I ...

The third phase of the Vietnam-Denmark Health Partnership Programme kicked off on June 23 as Deputy Minister of Health, Dr.

Sanofi and Regeneron Pharmaceuticals said they got Food and Drug Administration approval for anti-inflammatory drug Dupixent as a treatment for a rare skin disease, adding an eighth indication in ...

Paris: Sanofi has successfully priced its offering of euro 1.5 billion of notes across 2 tranches:€750 million fixed-rate ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. Gena Wang of ...